Table 6.1. Gene therapy agents in clinical trials

Product	Company	Composition	Indication	Phase
ADVEXIN®	Introgen Therapeutics	Adenoviral vector expressing the *p53* tumor suppressor gene	Squamous cell carcinoma of the head and neck	III
TNFerade™	GenVec	Adenoviral vector expressing the *TNF-α* gene	Pancreatic cancer	III
ProstAtak™	Advantagene	Adenovirus expressing the *HSV/tk* gene, followed by valacyclovir	Prostate cancer	III
OncoVEX^{GM-CSF}	BioVex	HSV-1 with deletions in ICP34.5 and ICP47 modified for expression of US11 and GM-CSF	Melanoma	III
Reolysin®	Oncolytics Biotech	Reovirus serotype 3 Dearing	Squamous cell carcinoma of the head and neck	III
PROSTVAC®	BN ImmunoTherapeutics	PROSTVAC-V-TRICOM: replication competent poxvirus with PSA plus three costimulatory molecules, B7.1, ICAM-1 and Lfa-3 PROSTVAC-F-TRICOM: nonreplicating virus with PSA plus B7.1, ICAM-1 and Lfa-3	Prostate cancer	III
JX-594	Jennerex	Thymidine kinase gene-inactivated oncolytic vaccinia virus expressing *GM-CSF* and *LacZ* genes	Liver cancer, melanoma, colorectal cancer	II

GM-CSF: Granulocyte–macrophage colony-stimulating factor.

JX-594 into primary or metastatic liver tumors has shown a good toxicology profile and signs of activity [54]. Another Phase I trial showed that JX-594 could selectively infect, replicate and express transgene products in metastatic tumors after intravenous infusion [55]. As well as the above described oncolytic viruses, a great deal of attention should be given to exploring the feasibility of systemically administered oncolytic viruses to treat metastatic disease [56].

Conclusion

The goal of cancer therapy is to eradicate not only the primary tumor but also any systemic metastasis that may reside in organs and tissues. Gene therapy

has the potential to act as highly specific, personalized medicine in cancer therapy. Vector systems and therapeutic genes have been considerably improved, and some promising strategies have finally reached Phase III trials. Earlier work has focused on vector and gene selection and the improvement of gene expression. The benefits of this work can be enhanced by adding other approaches, such as immunotherapy and chemotherapy. We hope that the current approach provides clinical success in the future.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Summary

- Several approaches for cancer gene therapy have been extensively studied, but none of them has been integrated into standard cancer therapy.
- Cancer gene therapy strategy is shifting away from the local treatment model toward more systemic approaches.
- Use of oncolytic virus and immunotherapy may heighten the therapeutic potency and cancer selectivity of gene therapy.
- Some of the gene therapeutic agents have entered the definitive clinical testing Phase III stage.

References

1 Hartwell LH, Kastan MB. Cell cycle control and cancer. *Science* 266(5192), 1821–1828 (1994).

2 Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis implications for cancer. *Cancer Metastasis Rev.* 14(1), 3–15 (1995).

3 Levine AJ, Momand J, Finlay CA. The *p53* tumour suppressor gene. *Nature* 351(6326), 453–456 (1991).

4 Clayman GL, el-Naggar AK, Lippman SM *et al.* Adenovirus-mediated *p53* gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. *J. Clin. Oncol.* 16(6), 2221–2232 (1998).

5 Swisher SG, Roth JA, Komaki R *et al.* Induction of *p53*-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral *p53* (INGN 201) and radiation therapy. *Clin. Cancer Res.* 9(1), 93–101 (2003).

6 Nemunaitis J, Swisher SG, Timmons T *et al.* Adenovirus-mediated *p53* gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. *J. Clin. Oncol.* 18(3), 609–622 (2000).

7 Nigro JM, Baker SJ, Preisinger AC *et al.* Mutations in the *p53* gene occur in diverse human tumour types. *Nature* 342(6250), 705–708 (1989).

8 Ladanyi M, Cha C, Lewis R *et al.* *MDM2* gene amplification in metastatic osteosarcoma. *Cancer Res.* 53(1), 16–18 (1993).

9 Kamijo T, Weber JD, Zambetti G *et al.* Functional and physical interactions of the ARF tumor suppressor with *p53* and Mdm2. *Proc. Natl Acad. Sci. USA* 95(14), 8292–8297 (1998).

10 Pomerantz J, Schreiber-Agus N, Liégeois NJ *et al.* The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of *p53*. *Cell* 92(6), 713–723 (1998).

11 Shono T, Tofilon PJ, Schaefer TS *et al.* Apoptosis induced by adenovirus-mediated *p53* gene transfer in human glioma correlates with site-specific phosphorylation. *Cancer Res.* 62(4), 1069–1076 (2002).

12 Zhang WW, Alemany R, Wang J *et al.* Safety evaluation of Ad5CMV-*p53 in vitro* and *in vivo*. *Hum. Gene Ther.* 6(2), 155–164 (1995).

13 Zhang WW, Fang X, Mazur W *et al.* High-efficiency gene transfer and high-level expression of wild-type *p53* in human lung cancer cells mediated by recombinant adenovirus. *Cancer Gene Ther.* 1(1), 5–13 (1994).

14 Parker LP, Wolf JK, Price JE. Adenoviral-mediated gene therapy with Ad5CMV*p53* and Ad5CMV*p21* in combination with standard therapies in human breast cancer cell lines. *Ann. Clin. Lab. Sci.* 30(4), 395–405 (2000).

15 Spitz FR, Nguyen D, Skibber JM *et al.* Adenoviral-mediated wild-type *p53* gene expression sensitizes colorectal cancer cells to ionizing radiation. *Clin. Cancer Res.* 2(10), 1665–1671 (1996).

16 Fujiwara T, Tanaka N, Kanazawa S *et al.* Multicenter Phase I study of repeated intratumoral delivery of adenoviral *p53* in patients with advanced non-small-cell lung cancer. *J. Clin. Oncol.* 24(11), 1689–1699 (2006).

17 Clayman GL, el-Naggar AK, Lippman SM *et al.* Adenovirus-mediated *p53* gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. *J. Clin. Oncol.* 16(6), 2221–2232 (1998).

18 Nemunaitis J, Clayman G, Agarwala SS *et al.* Biomarkers Predict *p53* Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. *Clin. Cancer Res.* 15(24), 7719–7725 (2009).

19 Zeimet AG, Marth C. Why did *p53* gene therapy fail in ovarian cancer? *Lancet Oncol.* 4(7), 415–422 (2003).

20 Old LJ. Tumor necrosis factor (TNF). *Science* 230(4726), 630–632 (1985).

21 Hallahan DE, Mauceri HJ, Seung LP *et al.* Spatial and temporal control of gene therapy using ionizing radiation. *Nat. Med.* 1(8), 786–791 (1995).

22 Senzer N, Mani S, Rosemurgy A *et al.* TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene a Phase I study in patients with solid tumors. *J. Clin. Oncol.* 22(4), 592–601 (2004).

23 Hecht JR, Farrell JJ, Senzer N *et al.* EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer a Phase I/II study. *Gastrointest. Endosc.* 75(2), 332–338 (2012).

24 Fillat C, Carrió M, Cascante A *et al.* Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system fifteen years of application. *Curr. Gene Ther.* 3(1), 13–26 (2003).

25 Fischer U, Steffens S, Frank S *et al.* Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. *Oncogene* 24(7), 1231–1243 (2005).

26 Balfour HH. Antiviral drugs. *N. Engl. J. Med,* 340(16), 1255–1268 (1999).

27 Eastham JA, Chen SH, Sehgal I *et al.* Prostate cancer gene therapy herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. *Hum. Gene Ther.* 7(4), 515–523 (1996).

28 Hall SJ, Mutchnik SE, Chen SH *et al.* Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. *Int. J. Cancer* 70(2), 183–187 (1997).

29 Duarte S, Carle G, Faneca H *et al.* Suicide gene therapy in cancer Where do we stand now? *Cancer Lett.* 324(2), 160–170 (2012).

30 Nasu Y, Saika T, Ebara S *et al.* Suicide gene therapy with adenoviral delivery of *HSV-tK* gene for patients with local recurrence of prostate cancer after hormonal therapy. *Mol. Ther.* 15(4), 834–840 (2007).

31 Kishimoto H, Kojima T, Watanabe Y *et al. In vivo* imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. *Nat. Med.* 12(10), 1213–1219 (2006).

32 Hu JC, Coffin RS, Davis CJ *et al.* A Phase I study of OncoVEX^{GM-CSF}, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. *Clin. Cancer Res.* 12(22), 6737–6747 (2006).

33 Liu BL, Robinson M, Han ZQ *et al.* ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. *Gene Ther.* 10(4), 292–303 (2003).

34 Senzer NN, Kaufman HL, Amatruda T *et al.* Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. *J. Clin. Oncol.* 27(34), 5763–5771 (2009).

35 Kaufman HL, Bines SD. OPTIM trial a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. *Future Oncol.* 6(6), 941–949 (2010).

36 Kim M, Chung YH, Johnston RN. Reovirus and tumor oncolysis. *J. Microbiol.* 45(3), 187–192 (2007).

37 Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. *Am. J. Hyg.* 77, 29–37 (1963).

38 Karapanagiotou EM, Roulstone V, Twigger K *et al.* Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. *Clin. Cancer Res.* 18(7), 2080–2089 (2012).

39 Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. *Arch. Virol.* 54(4), 307–315 (1977).

40 Strong JE, Coffey MC, Tang D *et al.* The molecular basis of viral oncolysis usurpation of the *Ras* signaling pathway by reovirus. *EMBO J.* 17(12), 3351–3362 (1998).

41 Strong JE, Lee PW. The *v-erbB* oncogene confers enhanced cellular susceptibility to reovirus infection. *J. Virol.* 70(1), 612–616 (1996).

42 Coffey MC, Strong JE, Forsyth PA *et al.* Reovirus therapy of tumors with activated Ras pathway. *Science* 282(5392), 1332–1334 (1998).

43 Prestwich RJ, Ilett EJ, Errington F *et al.* Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. *Clin. Cancer Res.* 15(13), 4374–4381 (2009).

44 Errington F, Steele L, Prestwich R *et al.* Reovirus activates human dendritic cells to promote innate antitumor immunity. *J. Immunol.* 180(9), 6018–6026 (2008).

45 Vidal L, Pandha HS, Yap TA *et al.* A Phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. *Clin. Cancer Res.* 14(21), 7127–7137 (2008).

46 Lolkema MP, Arkenau HT, Harrington K *et al.* A Phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. *Clin. Cancer Res.* 17(3), 581–588 (2011).

47 Comins C, Spicer J, Protheroe A *et al.* REO-10 a Phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. *Clin. Cancer Res.* 16(22), 5564–5572 (2010).

48 Harrington KJ, Karapanagiotou EM, Roulstone V *et al.* Two-stage Phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. *Clin. Cancer Res.* 16(11), 3067–3077 (2010).

49 Wang MC, Valenzuela LA, Murphy GP *et al.* Purification of a human prostate specific antigen. 1979 [classical article]. *J. Urol.* 167(3), 1226–1230 (2002).

50 Eder JP, Kantoff PW, Roper K *et al.* A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. *Clin. Cancer Res.* 6(5), 1632–1638 (2000).

51 DiPaola RS, Plante M, Kaufman H *et al.* A Phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7–1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. *J. Transl. Med.* 4, 1 (2006).

52 Kantoff PW, Schuetz TJ, Blumenstein BA *et al.* Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *J. Clin. Oncol.* 28(7), 1099–1105 (2011).

53 Mastrangelo MJ, Maguire HC, Eisenlohr LC *et al.* Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. *Cancer Gene Ther.* 6(5), 409–422 (1999).

54 Park BH, Hwang T, Liu TC *et al.* Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer a Phase I trial. *Lancet Oncol.* 9(6), 533–542 (2008).

55 Breitbach CJ, Burke J, Jonker D *et al.* Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature* 477(7362), 99–102 (2011).

56 Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics clinical proof-of-concept and future directions. *Cancer Res.* 67(2), 429–432 (2007).

Gene Therapy (2013) **20,** 112–118

www.nature.com/gt

SHORT COMMUNICATION

A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus

T Sasaki[1], H Tazawa[2,3], J Hasei[1], S Osaki [1], T Kunisada[1,4], A Yoshida[1], Y Hashimoto[3], S Yano[3], R Yoshida[3], S Kagawa[3], F Uno[3], Y Urata[5], T Ozaki[1] and T Fujiwara[3]

Adenovirus serotype 5 (Ad5) is frequently used as an effective vector for induction of therapeutic transgenes in cancer gene therapy or of tumor cell lysis in oncolytic virotherapy. Ad5 can infect target cells through binding with the coxsackie and adenovirus receptor (CAR). Thus, the infectious ability of Ad5-based vectors depends on the CAR expression level in target cells. There are conventional methods to evaluate the CAR expression level in human target cells, including flow cytometry, western blotting and immunohistochemistry. Here, we show a simple system for detection and assessment of functional CAR expression in human tumor cells, using the green fluorescent protein (GFP)-expressing telomerase-specific replication-competent adenovirus OBP-401. OBP-401 infection induced detectable GFP expression in CAR-expressing tumor cells, but not in CAR-negative tumor cells, nor in CAR-positive normal fibroblasts, 24 h after infection. OBP-401-mediated GFP expression was significantly associated with CAR expression in tumor cells. OBP-401 infection detected tumor cells with low CAR expression more efficiently than conventional methods. OBP-401 also distinguished CAR-positive tumor tissues from CAR-negative tumor and normal tissues in biopsy samples. These results suggest that GFP-expressing telomerase-specific replication-competent adenovirus is a very potent diagnostic tool for assessment of functional CAR expression in tumor cells for Ad5-based antitumor therapy.

Gene Therapy (2013) **20,** 112–118; doi:10.1038/gt.2011.213; published online 12 January 2012

Keywords: oncolytic virus; adenovirus; telomerase; sarcoma; GFP

INTRODUCTION

Adenovirus serotype 5 (Ad5) is widely and frequently used as an effective vector in cancer gene therapy and oncolytic virotherapy.[1–3] Adenovirus-mediated transgene transduction is a highly efficient method for induction of ectopic transgene expression in tumor cells.[1,2] The p53 tumor suppressor gene, which is a potential therapeutic transgene that may induce a very strong antitumor effect, has been transduced into tumor cells using a replication-deficient adenovirus vector (Ad-p53, Advexin, Intorgen Therapeutics, Inc., Austin, TX, USA), and Ad-p53 has been reported to induce an antitumor effect in clinical studies.[4–7] Recently, an Ad5-based replication-competent oncolytic adenovirus has been developed as a promising anticancer reagent for induction of tumor-specific cell lysis.[8,9] Ad5-based vectors infect human target cells through binding with the coxsackie and adenovirus receptor (CAR).[10] Thus, the infection efficiency of Ad5-based vectors mainly depends on the CAR expression level in tumor tissues.[11–17] Increased CAR expression has been frequently shown in tumor cells in various organs such as the brain,[18] thyroid,[19] esophagus,[20] gastrointestinal tract,[21] prostate,[14] bone and soft tissues.[22–24] However, tumor cells often show reduced CAR expression following tumor progression.[18,21,25,26] Decreased CAR expression has also been shown in tumor tissues after repeated injection of Ad-p53.[27,28] It is therefore necessary to assess the CAR expression level of target tumor tissues before and after Ad5-based cancer gene therapy and oncolytic virotherapy.

There are some conventional methods for evaluation of the CAR expression level in tumor tissues, such as flow cytometry, immunohistochemistry, western blotting and reverse transcription (RT)-PCR. Flow cytometry is mainly used to detect CAR-positive human tumor cell lines.[13,24,28,29] Immunohistochemistry is frequently used to assess CAR expression in various human tumor tissues.[11,14,20,23,25] Western blotting is usually performed to confirm the expression of many types of proteins including CAR in molecular biological experiments. Quantitative RT-PCR is also a useful method for evaluation of the mRNA expression of CAR.[18,22] Although these conventional methods can detect CAR expression in tumor tissues, it still remains unclear whether Ad5-based vectors really infect target tumor cells through binding with the CAR that is detected using conventional methods. Therefore, the development of a novel method for assessment of the level of expression of functional CAR in tumor tissues, which is what the Ad5-based vectors really bind, is required for Ad5-based anticancer therapy.

We previously developed a telomerase-specific replication-competent adenovirus OBP-301 (Telomelysin, Oncolys BioPharma, Inc., Tokyo, Japan) that drives the *E1A* and *E1B* genes under the human telomerase reverse transcriptase (*hTERT*) promoter.[8,29–31] OBP-301 infects both normal and tumor cells that express CAR, but replicates only in CAR-positive tumor cells in a telomerase-dependent manner. Furthermore, we recently generated a green fluorescent protein (GFP)-expressing telomerase-specific replication-

[1]Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; [2]Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan; [3]Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; [4]Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan and [5]Oncolys BioPharma, Inc., Tokyo, Japan. Correspondence: Professor T Fujiwara, Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
E-mail: toshi_f@md.okayama-u.ac.jp
Received 15 July 2011; revised 7 November 2011; accepted 5 December 2011; published online 12 January 2012

competent adenovirus OBP-401, which induces ectopic GFP expression in tumor cells, but not in normal cells.[32] OBP-401 infection efficiently induces GFP expression in metastatic tumor cells at regional lymph nodes[32] and liver,[33] circulating tumor cells in blood flow[34] and disseminated tumor cells in the abdominal cavity.[35] These results suggest that OBP-401 is a highly sensitive tool for the detection of tumor cells. Furthermore, Ad5-based OBP-401 would also be useful for induction of GFP expression in CAR-positive tumor cells, but not in CAR-negative tumor cells.

In the present study, we evaluated whether induction of GFP expression by OBP-401 infection is associated with CAR expression in tumor cells. OBP-401-mediated GFP induction was further examined in xenograft tumor tissues that have different levels of CAR expression and in surrounding normal tissues.

RESULTS AND DISCUSSION

Assessment of an OBP-401 infection protocol for the detection of CAR-positive tumor cells

We recently demonstrated that the level of CAR expression that was detected using flow cytometry was significantly associated with OBP-301-mediated cytopathic activity in human bone and soft tissue sarcoma cells.[29] Furthermore, OBP-401 infection has been shown to induce GFP expression 24 h after infection of human sarcoma cells.[34] To evaluate whether GFP expression that is induced by OBP-401 infection is associated with CAR expression in tumor cells, we used three human sarcoma cell lines (OST, NMFH-1 and OUMS-27) that have different levels of CAR expression, as previously reported.[29] Flow cytometric analysis confirmed that OST cells showed detectable CAR expression, whereas cells of the NMFH-1 and OUMS-27 sarcoma cell lines had no detectable CAR expression (Figure 1a).

To determine suitable conditions for OBP-401 infection in order to detect CAR-positive tumor cells, OST sarcoma cells were infected with OBP-401 at multiplicity of infections (MOIs) of 1, 10 and 100 plaque-forming units (PFU) per cell over 24 h (Figure 1b and c). Twelve hours after infection, only OBP-401 infection at an MOI of 100 had induced GFP expression in all of the OST cells. Twenty-four hours after infection, OBP-401 infection at MOIs of 10 and 100 had induced ectopic GFP expression in all of the OST cells, whereas OBP-401 infection at an MOI of 1 had induced GFP expression in about 80% of the OST cells. These results indicate that OBP-401 infection at an MOI of greater than 10 is necessary to efficiently detect CAR-positive tumor cells 24 h after infection.

To subsequently determine a suitable condition for OBP-401 infection that would exclude CAR-negative tumor cells, the NMFH-1 and OUMS-27 sarcoma cells that do not express CAR were infected with OBP-401 at MOIs of 10 and 100 for 60 h (Figures 1d and e). NMFH-1 cells expressed GFP at 24 and 48 h after OBP-401 infection at MOIs of 100 and 10, respectively. In contrast, OUMS-27 cells exhibited no GFP expression after OBP-401 infection. To investigate the different GFP expression between these CAR-negative tumor cells, expression of integrins, $\alpha v\beta 3$ and $\alpha v\beta 5$, was further examined by flow cytometry. NMFH-1 cells showed twofold higher expression of integrin $\alpha v\beta 3$ compared with OUMS-27 cells, whereas $\alpha v\beta 5$ expression was similar in these cells (Supplementary Figure S1a). These results indicate that OBP-401 infection at an MOI of 10 for 24 h is a suitable protocol for distinguishing CAR-negative tumor cells from CAR-positive tumor cells, when CAR-negative tumor cells express integrin molecules.

Relationship between OBP-401-induced GFP expression and CAR expression

To evaluate whether OBP-401-induced GFP expression correlates with CAR expression in tumor cells, six human sarcoma cell lines (OST, U2OS, NOS-10, MNNG/HOS, NMFH-1 and OUMS-27) and normal human lung fibroblasts (NHLF) cells that have different levels of CAR expression (Figure 1a and Supplementary Figure S1b) were infected with OBP-401 at an MOI of 10 for 24 h, and the GFP-positive cells in each cell type were analyzed under fluorescence microscopy (Figures 2a and b). OBP-401 infection-induced GFP expression from 12 h after infection and, after 24 h, more than 40% of all CAR-positive tumor cells (OST, U2OS, NOS-10 and MNNG/HOS) were detected as GFP-positive cells. However, no GFP-positive cells were detected in the CAR-negative tumor cells (NMFH-1, OUMS-27), or in the normal NHLF cells, 24 h after infection. Furthermore, OBP-401-mediated GFP induction in CAR-positive tumor cells was suppressed by blocking CAR proteins with anti-CAR antibody (Supplementary Figure S2). To assess the GFP expression level in all tumor and normal cells in a more quantitative manner, we quantified the level of GFP fluorescence in each cell type 24 h after infection using a fluorescence microplate reader (Figure 2c). We also quantified the level of CAR expression in these cells by calculating the mean fluorescence intensity in flow cytometric analysis (Figure 2d). GFP fluorescence was detected in CAR-positive tumor cells, but not in either CAR-negative tumor cells or in CAR-positive normal cells. There was a significant relationship between the CAR expression level and the GFP fluorescence level ($r=0.885$; $P=0.019$) (Figure 2e). These results indicate that OBP-401-mediated GFP expression is highly associated with CAR expression in tumor cells.

Comparison of the potential of OBP-401-mediated GFP induction and of conventional methods for CAR detection

To estimate the potential of OBP-401-mediated GFP induction for the detection of CAR-positive tumor cells, we compared the above protocol using OBP-401 with western blot analysis and immunocytochemistry. CAR expression was detected in OST, U2OS and NOS-10 sarcoma cells, but not in CAR-positive MNNG/HOS sarcoma cells, using western blot analysis (Supplementary Figure S3a). In contrast, only OST cells displayed a positive CAR signal using immunocytochemistry, whereas the CAR signal of the other three CAR-positive tumor cells was almost as weak as that from CAR-negative tumor cells (Supplementary Figure S3b). CAR expression was also not detected in CAR-positive NHLF cells by either western blot analysis or by immunocytochemistry. These results suggest that the GFP induction protocol using OBP-401 is more sensitive for the detection of CAR-positive tumor cells than conventional methods.

OBP-401-mediated GFP induction was detected in MNNG/HOS sarcoma cells that expressed a low level of CAR (Figure 2c), although neither western blot analysis nor immunocytochemistry detected CAR in these cells (Supplementary Figure S3). Furthermore, although conventional methods may be able to detect high CAR expression in tumor cells, whether the CAR expression that is detected by conventional methods is really functional for binding with Ad5-based vectors still remains unclear. In contrast, as OBP-401 is an Ad5-based vector that expresses a fluorescent *GFP* gene, OBP-401-induced GFP expression directly proves that the CAR that is expressed is functional for Ad5-based vector binding. Thus, the OBP-401-mediated GFP induction strategy is a potential diagnostic method that can efficiently and directly assess functional CAR expression in tumor cells.

OBP-401-mediated GFP induction in xenograft tumor and normal tissues with different CAR expression

Finally, to investigate the potential of the OBP-401-mediated method for the detection of CAR expression in tumor and normal tissues, we used this method to analyze CAR expression of human xenograft tumor tissues, that do or do not express CAR, as well as of surrounding normal muscle tissues, which have been previously shown to lose CAR expression.[36] CAR-positive OST sarcoma cells or CAR-negative OUMS-27 sarcoma cells were inoculated into nude



Figure 1. Establishment of a suitable protocol for the detection of CAR expression using OBP-401. (**a**) The level of CAR expression on three human sarcoma cell lines (OST, NMFH-1 and OUMS-27) was analyzed using flow cytometry. The cells were incubated with a monoclonal anti-CAR (RmcB) antibody and the signal was detected using a fluorescent isothiocyanate (FITC)-labeled secondary antibody. The mean fluorescence intensity (MFI), which is a measure of CAR and integrin expression, was calculated for each cell and is shown at the top right of each graph. (**b**) Time-lapse images of OST cells, which displayed the highest CAR expression, were recorded for 24 h after OBP-401 infection at MOIs of 1 and 10 PFU per cell. Representative images taken at the indicated time points and MOIs show cell morphology that was analyzed using phase-contrast microscopy (top panels) and GFP expression that was analyzed using fluorescence microscopy (bottom panels). Original magnification: × 80. (**c**) The percentage of GFP-positive cells was counted in OST cells at the indicated time points after OBP-301 infection at MOIs of 1, 10 and 100 PFU per cell. (**d**) Time-lapse images of non-CAR-expressing OUMS-27 and NMFH-1 cells were recorded for 60 h after OBP-401 infection at MOIs of 10 and 100 PFU per cell. Representative images taken at the indicated time points and MOIs show cell morphology that was analyzed using phase-contrast microscopy (top panels) and GFP expression that was analyzed using fluorescence microscopy (bottom panels). Original magnification: × 80. (**e**) The percentage of OUMS-27 and NMFH-1 GFP-positive cells was counted at the indicated time points after OBP-301 infection at MOIs of 10 and 100 PFU per cell.

mice to develop xenograft tumors. After resection of the OST tumors, the OUMS-27 tumors and normal muscle tissue, the tissues were subjected to the protocol for OBP-401-mediated GFP induction using a three-step procedure (Figure 3a) as follows; step 1: OBP-401 infection for 24 h, step 2: washing with PBS and step 3: observation under a fluorescence microscope. As shown in Figure 3b, OBP-401 infection-induced GFP expression in CAR-positive OST tumor tissues, but not in CAR-negative OUMS-27 tumor tissues or in normal muscle tissue. These results suggest that OBP-401-mediated GFP induction is a simple and useful method for the detection of CAR expression by tumor tissues.

Flow cytometry is a highly sensitive conventional method for the detection of cell surface CAR expression, which is associated with the therapeutic efficacy of Ad5-based vectors in tumor cells.[13,24,28,29] However, as many tumor cells tightly bind to each other or to normal stromal cells within tumor tissues, the preparation of single tumor cells is not easy, and therefore flow cytometry is an inadequate method for the detection of CAR expression in tumor tissues. In contrast, the preparation of single tumor cells is not necessary for the OBP-401-mediated GFP induction protocol. Furthermore, assay of OBP-401-induced GFP expression was more sensitive than flow cytometry (Figure 2d) in distinguishing CAR-positive normal cells from CAR-positive tumor cells (Figure 2c). Thus, the OBP-401-mediated GFP induction method is a simple and tumor-specific system for the detection of CAR expression in tumor tissues.

Fluorescent proteins including GFP have great potentials to visualize tumor cells in real time on the *in vivo* setting.[37,38]



Figure 2. *In vitro* CAR-dependent GFP expression induced by OBP-401 infection. (**a**) The percentage of GFP-positive cells in all tumor and normal cells was counted at the indicated time points after OBP-301 infection at an MOI of 10 PFU per cell. (**b**) Time-lapse images of all tumor and normal cells were recorded for 24 h after infection with OBP-401 at an MOI of 10 PFU per cell. Representative images taken at the indicated time points show cell morphology that was analyzed using phase-contrast microscopy (top panels) and GFP expression that was analyzed using fluorescence microscopy (bottom panels). Original magnification: ×80. (**c**) Quantitative assessment of the level of GFP fluorescence in all tumor and normal cells 24 after OBP-401 infection at an MOI of 10 PFU per cell, using a fluorescent microplate reader with excitation/emission at 485 nm/528 nm. The intensity of GFP fluorescence was evaluated based on the brightness determinations used as relative fluorescence units (RFU). (**d**) The mean fluorescent intensity (MFI) of (CAR) expression on human sarcoma cells and normal fibroblasts. The cells were incubated with a monoclonal anti-CAR (RmcB) antibody, followed by a FITC-labeled secondary antibody, and were analyzed using flow cytometry. (**e**) Relationship between the level of GFP fluorescence and CAR expression in all tumor and normal cells after OBP-401 infection. The slope represents the inverse correlation between these two factors. Statistical significance was determined as $P<0.05$, after analysis of Pearson's correlation coefficient.

We previously reported that OBP-401 can efficiently induce GFP expression in small populations of metastatic tumor cells at various regions *in vivo*.[32-35] In this study, we further demonstrated that OBP-401-mediated GFP expression provides us the important information for detection of CAR-positive tumor cells. OBP-401 with *hTERT* gene promoter-induced GFP expression in CAR-positive tumor cells with telomerase activity, but not CAR-positive normal cells without telomerase activity (Figure 2c). There was significant relationship between the CAR expression and the GFP expression in tumor cells (Figure 2d). Among the four CAR-positive tumor cells, U2OS cells showed low GFP expression compared with high CAR expression (Figure 1a and 2c). As we recently reported that U2OS cells showed low *hTERT* mRNA expression, the low activity of *hTERT* gene promoter in tumor cells would affect OBP-401-mediated GFP expression. However, as various types of human cancer cells frequently show high telomerase activities,[39] OBP-401-mediated GFP induction system would be widely useful method to evaluate CAR expression in tumor cells.

Previous reports have suggested that *ex vivo* infection of human cancer specimens with a GFP-expressing replication-deficient adenovirus[40] or a replication-selective oncolytic adenovirus[41] is a useful method for assessment of the transduction efficacy or cytopathic activity, respectively, of Ad5-based vectors in individual tumor tissues. In this study, we confirmed that the GFP-expressing telomerase-specific oncolytic adenovirus OBP-401 is useful for detection of CAR-positive tumor tissues through induction of GFP expression (Figure 3b). Interestingly, OBP-401-infected OST tumor tissues showed heterogenous GFP expression (Figure 3b), although GFP expression was induced in all OBP-401-infected OST cells *in vitro* (Figure 2b). Our finding of heterogenous GFP expression in tumor tissues, which indicates heterogenous CAR expression, is consistent with a previously reported heterogeneity in CAR expression.[42] As several factors such as hypoxia[43] and cell cycle status[44] have been suggested to affect CAR expression in tumor cells, factors in the tumor microenvironment may be involved in the heterogenous CAR expression in tumor cells.



Figure 3. A simple method for detection of CAR expression in tumor tissues using OBP-401 infection. (**a**) Outline of the 3-step procedure; step 1: infection with OBP-401, step 2: washing with PBS and step 3: observation under a fluorescence microscope. Tumor tissues ($2 \times 2 \times 2\,mm^3$) were infected with OBP-401 at a concentration of 2.4×10^6 PFU for 24 h, were washed with PBS and were observed using fluorescence microscopy. (**b**) Assessment of GFP expression in the CAR-positive OST tumor (left panel), the CAR-negative OUMS-27 tumor (middle panel) and normal muscle tissues (right panel) under a fluorescence microscope. Original magnification: $\times 30$.

Furthermore, as OBP-401 induces tumor-specific GFP expression, normal stromal or epithelial cells may be involved in heterogenous GFP expression in tumor tissues.

In conclusion, we have demonstrated that the GFP-expressing telomerase-specific replication-competent adenovirus OBP-401 is a promising fluorescence imaging tool for the detection of functional and tumor-specific CAR expression in tumor tissues. OBP-401-mediated GFP induction is a simple and highly sensitive method for analysis of tumor cells compared with conventional methods. This novel CAR detection system using OBP-401 has the potential of being widely applicable to assessment of predictive biomarkers for Ad5-based vector-mediated anticancer therapy.

MATERIALS AND METHODS

Cell lines

The human osteosarcoma cell line OST was kindly provided by Dr Satoru Kyo (Kanazawa University, Ishikawa, Japan). The human osteosarcoma cell line U2OS and the transformed embryonic kidney cell line 293 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). The human osteosarcoma cell line NOS-10[45] and the human malignant fibrous histiocytoma cell line NMFH-1[46] were kindly provided by Dr Hiroyuki Kawashima (Niigata University, Niigata, Japan). The human osteosarcoma cell line MNNG/HOS was purchased from DS Pharma Biomedical (Osaka, Japan). The chondrosarcoma cell line OUMS-27 was previously established in our laboratory.[47] The normal human lung fibroblast cell line NHLF was obtained from TaKaRa Biomedicals (Kyoto, Japan). These cells were propagated as monolayer cultures in the medium recommended by the manufacturer. All media were supplemented with 10% heat-inactivated fetal bovine serum, 100 units ml^{-1} penicillin and 100 $\mu g\,ml^{-1}$ streptomycin. The cells were maintained at 37 °C in a humidified atmosphere containing 5% CO_2.

Recombinant adenoviruses

We previously generated and characterized OBP-401, which is a telomerase-specific replication-competent adenovirus variant, in which the *hTERT* promoter element drives the expression of *E1A* and *E1B* genes that are linked to an internal ribosome entry site, and in which the *GFP* gene is inserted into the E3 region under a cytomegalovirus promoter.[32,34] The virus was purified by ultracentrifugation using cesium chloride step gradients. Viral titers were determined by a plaque-forming assay using 293 cells and viruses were stored at −80 °C.

Flow cytometry

The cells (5×10^5 cells) were labeled with the mouse monoclonal anti-CAR (RmcB; Upstate Biotechnology, Lake Placid, NY, USA) antibody for 30 min at 4 °C. The cells were then incubated with fluorescent isothiocyanate-conjugated rabbit anti-mouse IgG second antibody (Zymed Laboratories, San Francisco, CA, USA) and were analyzed using flow cytometry (FACS Array; Becton Dickinson, Mountain View, CA, USA). The mean fluorescence intensity of CAR for each cell line was determined by calculating the differences between the mean fluorescence intensity in antibody-treated and non-treated cells in triplicate experiments.

Time-lapse confocal laser microscopy

The cells (1×10^5 cells per dish) were seeded in 35 mm glass-based dishes 20 h before virus infection. OST cells were infected with OBP-401 at an MOI of 1, 10 or 100 PFU per cell for 24 h. NMFH-1 and OUMS-27 cells were infected with OBP-401 at an MOI of 10 or 100 PFU per cell for 60 h. Other cells were infected with OBP-401 at an MOI of 10 PFU per cell for 24 h. Phase-contrast and fluorescence time-lapse recordings were obtained to concomitantly analyze cell morphology and GFP expression using an inverted FV10i confocal laser scanning microscopy (OLYMPUS; Tokyo, Japan). Photographic images were taken every 5 min. The percentage of GFP-positive cells in each field was calculated using the formula: the number of CAR-positive cells / the total number of CAR-positive and CAR-negative cells $\times 100$.

Fluorescence microplate assay

The cells (5×10^3 cells per well) were seeded on 96-well black bottomed culture plates and were incubated for 20 h before virus infection. The cells were infected with OBP-401 at an MOI of 10 for 24 h. The level of expression of GFP fluorescence was measured using a fluorescent microplate reader (DS Pharma Biomedical; Osaka, Japan) with excitation/emission at 485 nm/528 nm. The mean expression of GFP fluorescence in each cell was calculated in triplicate experiments, as previously reported.[34]

Animal experiments

Animal experimental protocols were approved by the Ethics Review Committee for Animal Experimentation of Okayama University School of Medicine. OST and OUMS-27 cells (5×10^6 cells per site) were inoculated into the flank of female athymic nude mice aged 6 to 7 weeks (Charles River Laboratories, Wilmington, MA, USA). Palpable tumors developed within 14 to 21 days and were permitted to grow to ~5 to 6 mm in diameter. At that stage, tumor and normal muscle tissues were resected. The tumor and normal tissues ($2 \times 2 \times 2\,mm^3$) were placed in 96-well plates with culture medium. As single tumor cell is about 10 μm in diameter, we considered that there are 2.4×10^5 cells on the surface area of each sample tissue. Then, we infected each sample tissue with 2.4×10^6 PFU (10 MOI per sample) of OBP-401 for 24 h. After washing with PBS, tumor and normal tissues were again placed in 96-well plates with culture medium and analyzed using an inverted fluorescence microscope (OLYMPUS).

Statistical analysis

Data are expressed as means ± s.d. Student's *t*-test was used to compare differences between groups. Pearson's product-moment correlation coefficients were calculated using PASW statistics software version 18 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as when the *P* value was less than 0.05.

ABBREVIATIONS

Ad5, Adenovirus serotype 5; CAR, coxsackie and adenovirus receptor; GFP, green fluorescent protein; RT-PCR, reverse transcription-polymerase chain reaction; hTERT, human telomerase reverse transcriptase; MOI, multiplicity of infection;